{
  "_originalData": {
    "title": "Peptoniphilus sp - Finegoldia sp",
    "last_updated": "2022-11-08",
    "classification": {
      "description": "Anaerobic streptococcus.",
      "species_included": [
        "Peptoniphilus anaerobius",
        "Peptoniphilus stomatis",
        "Finegoldia magna"
      ],
      "former_name": "Peptostreptococcus species",
      "susceptibility_note": "Species might vary somewhat in in vitro susceptibility."
    },
    "clinical_setting": {
      "summary": "These are anaerobic streptococci that are part of the normal flora of the upper respiratory tract, pharynx, GI tract, and vagina.",
      "infections": "Local infections like periodontal disease or endometritis can occur. Bacteremia can also ensue and may be complicated by brain abscess, endocarditis, or other focal infections."
    },
    "treatment_regimens": {
      "primary": [
        {
          "drug": "Penicillin G",
          "dosage": "Dose depends on the site of infection. For meningitis/brain abscess, the dose is 18-24 million units per day."
        }
      ],
      "alternative": [
        {
          "drug": "Metronidazole",
          "dosage": "500 mg IV q8h"
        },
        {
          "drug": "Clindamycin",
          "dosage": "Dose depends on the site of infection. IV dose ranges from 600-900 mg IV q8h (see Comment)."
        }
      ]
    },
    "comments": {
      "clindamycin_resistance": "One French study reported 28% resistance. Another study showed that the majority, but not all, of isolates were susceptible to Clindamycin, Moxifloxacin, Metronidazole, and Penicillins.",
      "case_reports": [
        "A case report described successful treatment of a brain abscess with Linezolid.",
        "A series of 15 cases of Peptoniphilus sp bloodstream infection has been published."
      ]
    }
  },
  "_metadata": {
    "originalKeys": [
      "title",
      "last_updated",
      "classification",
      "clinical_setting",
      "treatment_regimens",
      "comments"
    ],
    "conversionTimestamp": "2025-07-15T03:16:49.259Z",
    "sourceFormat": "mixed"
  },
  "identity": {
    "bacteriumName": {
      "sources": [
        "title"
      ],
      "value": "Peptoniphilus sp - Finegoldia sp"
    },
    "aliases": {
      "sources": [
        "aliases"
      ],
      "value": []
    }
  },
  "treatmentData": {
    "treatmentData": {
      "_treatmentMetadata": {
        "originalFormat": "mixed"
      },
      "standardizedRegimens": [],
      "preservedData": {
        "title": "Peptoniphilus sp - Finegoldia sp",
        "last_updated": "2022-11-08",
        "classification": {
          "description": "Anaerobic streptococcus.",
          "species_included": [
            "Peptoniphilus anaerobius",
            "Peptoniphilus stomatis",
            "Finegoldia magna"
          ],
          "former_name": "Peptostreptococcus species",
          "susceptibility_note": "Species might vary somewhat in in vitro susceptibility."
        },
        "clinical_setting": {
          "summary": "These are anaerobic streptococci that are part of the normal flora of the upper respiratory tract, pharynx, GI tract, and vagina.",
          "infections": "Local infections like periodontal disease or endometritis can occur. Bacteremia can also ensue and may be complicated by brain abscess, endocarditis, or other focal infections."
        },
        "treatment_regimens": {
          "primary": [
            {
              "drug": "Penicillin G",
              "dosage": "Dose depends on the site of infection. For meningitis/brain abscess, the dose is 18-24 million units per day."
            }
          ],
          "alternative": [
            {
              "drug": "Metronidazole",
              "dosage": "500 mg IV q8h"
            },
            {
              "drug": "Clindamycin",
              "dosage": "Dose depends on the site of infection. IV dose ranges from 600-900 mg IV q8h (see Comment)."
            }
          ]
        },
        "comments": {
          "clindamycin_resistance": "One French study reported 28% resistance. Another study showed that the majority, but not all, of isolates were susceptible to Clindamycin, Moxifloxacin, Metronidazole, and Penicillins.",
          "case_reports": [
            "A case report described successful treatment of a brain abscess with Linezolid.",
            "A series of 15 cases of Peptoniphilus sp bloodstream infection has been published."
          ]
        }
      }
    }
  },
  "additionalData": {
    "antimicrobialStewardship": {
      "sources": [
        "antimicrobial_stewardship",
        "antimicrobialStewardship"
      ],
      "value": []
    },
    "comments": {
      "preservedStructure": {
        "originalFormat": "object",
        "content": {
          "clindamycin_resistance": "One French study reported 28% resistance. Another study showed that the majority, but not all, of isolates were susceptible to Clindamycin, Moxifloxacin, Metronidazole, and Penicillins.",
          "case_reports": [
            "A case report described successful treatment of a brain abscess with Linezolid.",
            "A series of 15 cases of Peptoniphilus sp bloodstream infection has been published."
          ]
        }
      }
    },
    "diagnosis": {
      "sources": [
        "diagnosis"
      ],
      "value": []
    },
    "allOtherKeys": {
      "last_updated": "2022-11-08",
      "treatment_regimens": {
        "primary": [
          {
            "drug": "Penicillin G",
            "dosage": "Dose depends on the site of infection. For meningitis/brain abscess, the dose is 18-24 million units per day."
          }
        ],
        "alternative": [
          {
            "drug": "Metronidazole",
            "dosage": "500 mg IV q8h"
          },
          {
            "drug": "Clindamycin",
            "dosage": "Dose depends on the site of infection. IV dose ranges from 600-900 mg IV q8h (see Comment)."
          }
        ]
      }
    }
  }
}